BRAF positive

P1, N=159, Recruiting, Haisco Pharmaceutical Group Co., Ltd.

P=N/A, N=10, Not yet recruiting, Sona Nanotech Inc | Trial completion date: Jun 2026 --> Dec 2026 | Trial primary completion date: Jun 2026 --> Dec 2026

P1, N=47, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed | N=33 --> 47

P2, N=92, Beijing Cancer Hospital (Peking University Cancer Hospital); Beijing Cancer Hospital (Peking University Cancer Hospital)

P2, N=50, Active, not recruiting, Alliance for Clinical Trials in Oncology | Suspended --> Active, not recruiting | N=186 --> 50

BRAF expression and concomitant BRAF-KRAS expression was seen in 41.6% and 16.6% respectively of all the biopsy proven malignant cases. The risk of malignancy for BRAF+ FNAC smears was 90% and for BRAF-KRAS+smears, it was 100.

Across the United States, the population-adjusted incidence of urothelial mutations in voided urine was not associated with municipal water TTHMs, but was instead associated in cross-sectional analyses with age, neutered status, higher regional test submission rates and previously reported high-risk breeds for UC (Scottish terriers, West Highland white terriers, Shetland sheepdogs, beagles and wirehaired fox terriers). The higher RR for a positive BRAF or BRAF-PLUS test in Las Vegas versus Reno could be solely due to higher test submission rates (2.97 versus 0.97 per 1000 dogs) but could also reflect other environmental exposures not considered in this study.

Genetic test showed a positive BRAF V600E gene mutation. Treatment with dabrafenib and trametinib was initiated nine days after lenvatinib was discontinued.

MWA achieved effective local control with low complication rates in T1N0M0 PTC regardless of BRAF V600E mutation status.

It was determined that that the positivity of BRAF, TERT, and both mutations was associated with large tumor size, and the extra thyroidal spread was higher in BRAF positivity, but there was no statistically significant difference in metastasis, recurrence, and survival. The presence of BRAF and TERT mutations should be evaluated with more comprehensive studies in terms of clinical benefit prior to their routine use in our country.

The patient was initiated on ipilimumab and nivolumab immunotherapy, which was well tolerated with a favourable response. This case illustrates the critical role of PET-CT in distinguishing tumour thrombus from embolic disease and demonstrates the value of EBUS as a minimally invasive, safe, and effective diagnostic tool in high-risk settings. It also highlights how perseverance in diagnostic efforts can facilitate early treatment, even in complex and high-risk scenarios.

The study showed an even distribution of colorectal adenocarcinoma incidence between males and females, with the highest rates of diagnosis in patients aged more than 50 years. Patients with stage III and IV disease had a higher rate of serum CEA elevation as compared to stage I and II.